CEACAM5 and familial pancreatic carcinoma: Tumor biomarkers can be further combined with certain mutations to improve the sensitivity for the detection of cancers, such as the carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), osteopontin, and hepatocyte growth factor that are combined with KRAS mutation to detect pancreatic cancer [11].